November 1st 2024
Clinicians discussed the complexities of diagnosing Long COVID, emphasizing the need for improved biomarkers and diagnostic technologies to better serve affected patients.
October 29th 2024
The CANOPY Phase 3 clinical trial demonstrated a reduced risk of symptomatic COVID-19, including a 64% reduction during the off-drug follow-up period.
October 29th 2024
Shionogi’s ensitrelvir demonstrated reduction of symptoms in phase 3 trial.
October 24th 2024
Important vaccine updates, including a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, a pneumococcal vaccine for adults aged 50 and older, and more.
October 11th 2024
A NIH-funded study focused on analyzing the Wuhan strain in unvaccinated patients with COVID-19. Results showed those with certain blood types seemed to fare worse significantly increasing their risk for cardiovascular events and mortality.
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
No Increased Risk of Neurological Conditions After COVID-19 Vaccination
March 17th 2022A study of over 8 million participants found no correlation between COVID-19 vaccination and developing neurological conditions. However, a risk of some neurological conditions was increased after COVID-19 infection.
Read More
Oral Nirmatrelvir Highly Effective Against COVID-19 in Phase 2/3 Trial
March 16th 2022Pfizer’s COVID-19 pill Paxlovid, which includes nirmatrelvir and ritonavir, reduced the risk of hospitalization and death by 89% among adults at high risk for severe disease, recently published phase 2/3 trial data show.
Read More
With New Variants, COVID-19 Vaccination Mildly Effective in Children
March 15th 2022In children and adolescents, the Pfizer-BioNTech vaccine was only mildly effective against symptomatic and asymptomatic COVID-19 infections. Broken down by variant, Omicron infections were more likely to occur and more likely to be asymptomatic.
Read More
Addressing COVID-19 Vaccine Efficacy Challenges in Younger Children
March 4th 2022This week, one of the m-RNA COVID-19 vaccine’s effectiveness was shown to drop from 68% to 12% in children 5-11 years old within a month. This data raises concerns of what should be done to protect this pediatric population.
Watch
2 Commerce Drive
Cranbury, NJ 08512